The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|June 18, 2006
- Applied Clinical Trials-06-19-2006
- Volume 0
- Issue 0
TAKE Solutions, ACI, and OnSphere Merge to Create TAKE Solutions, Global Life Sciences and the OneClinical Brand
OneClinical Provides a Full Spectrum of Software Products and Services for the Regulated Life Sciences Industry.
Advertisement
Princeton, NJ-June 12, 2006-Today TAKE Solutions, Inc. announced the formation of the OneClinical™ brand of life sciences offerings as part of its merger with Applied Clinical Intelligence (Philadelphia, PA) and OnSphere Corporation (Raleigh, NC). OneClinical combines a full spectrum of proven data and document management software products and services for clinical trials, drug and device development lifecycles.
"The merger of TAKE Solutions, ACI, and OnSphere enhances our ability to help our clients improve efficiencies in drug and medical device development and product safety. We can now offer our clients global scalability as well as a robust suite of regulatory-compliant process efficiency software" said Dr. Jonathan Seltzer, President, ACI & Chief Medical Officer, TAKE Solutions Global Life Sciences.
Articles in this issue
over 20 years ago
BBK Healthcare, Inc. Evolves to Become BBK Worldwideover 20 years ago
Datafarm Announces the Release of Web-Based eCTD ViewerAdvertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5